ALNY News and Press, Alnylam Pharmaceuticals Inc. From 12/21/21

– Annual progress report highlights the breadth of innovative and collaborative initiatives that support accessibility of RNAi therapeutics for people who can benefit worldwide – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics co...

– Phase 2 Study will Evaluate the Safety and Efficacy of Lumasiran in Patients with Recurrent Kidney Stone Disease and Elevated Urinary Oxalate Levels – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced tha...

– Company Expects to Initiate a Phase 1/2 Study for ALN-XDH in Gout in Early 2022, with Initial Human Data in Late 2022 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a c...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

Alnylam Pharmaceuticals (NASDAQ:ALNY) has submitted a sNDA to the FDA for a label expansion of Oxlumo to include reducing plasma oxalate in advanced primary hyperoxaluria type 1 (PH1). A Type II Filing Variation for Oxlumo (lumasiran) was also submitted European Medicines Agency . The ap...

-Findings From the ILLUMINATE-C Phase 3 Study Showed Substantial Reductions in Plasma Oxalate in PH1 Patients with End-Stage Kidney Disease, Including Patients on Hemodialysis- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced...

Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

- Recognition Marks Alnylam’s Seventh Year in a Row on this Prestigious List, and its First Time Ranking #1 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has ranked first in Boston Globe’s 2021 Top...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: Evercore ISI 4 th Annual HealthCONx Conference on Tuesday, November 30, 20...